New Horizons for Probucol, an Old, Mysterious Drug.
作者信息
Yamashita Shizuya, Masuda Daisaku, Matsuzawa Yuji
机构信息
Department of Cardiology, Rinku General Medical Center.
Sumitomo Hospital.
出版信息
J Atheroscler Thromb. 2021 Feb 1;28(2):100-102. doi: 10.5551/jat.ED132. Epub 2020 Jun 5.
Abstract
摘要
相似文献
1
New Horizons for Probucol, an Old, Mysterious Drug.普罗布考，一种古老而神秘药物的新前景。
J Atheroscler Thromb. 2021 Feb 1;28(2):100-102. doi: 10.5551/jat.ED132. Epub 2020 Jun 5.
2
New Evidence of Probucol on Cardiovascular Events.普罗布考对心血管事件影响的新证据
J Atheroscler Thromb. 2021 Feb 1;28(2):97-99. doi: 10.5551/jat.ED155. Epub 2020 Nov 21.
3
Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).普罗布考用于冠心病患者二级预防动脉粥样硬化事件的试验（前瞻性）。
J Atheroscler Thromb. 2021 Feb 1;28(2):103-123. doi: 10.5551/jat.55327. Epub 2020 Apr 24.
4
Probucol reduces lysophosphatidylcholines in low-density lipoprotein.普罗布考可降低低密度脂蛋白中的溶血磷脂酰胆碱。
Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):787-92. doi: 10.1007/s002280050698.
5
[Treatment with statins: lowering of cholesterol or more?].[他汀类药物治疗：降低胆固醇还是另有更多作用？]
Praxis (Bern 1994). 2006 Jan 25;95(4):107-10. doi: 10.1024/0369-8394.95.4.107.
6
[Probucol].[普罗布考]
Nihon Rinsho. 2007 Jul 28;65 Suppl 7:470-5.
7
Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats.普罗布考可降低高脂血症吉田大鼠的肝脏胆固醇分泌。
Atherosclerosis. 1996 Jan 26;119(2):223-33. doi: 10.1016/0021-9150(95)05651-3.
8
Dissociating HDL cholesterol from cardiovascular risk.将高密度脂蛋白胆固醇与心血管风险分离开来。
Lancet. 2010 Jul 31;376(9738):305-6. doi: 10.1016/S0140-6736(10)61021-5. Epub 2010 Jul 23.
9
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.阿托伐他汀治疗对有心血管风险的2型糖尿病患者的长期（18个月）疗效。
Nutr Metab Cardiovasc Dis. 2002 Feb;12(1):29-35.
10
Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.普罗布考治疗可减轻渡边遗传性高脂血症兔的主动脉粥样硬化。
Atherosclerosis. 1998 Mar;137(1):13-22. doi: 10.1016/s0021-9150(97)00243-8.
引用本文的文献
1
Oral administration of butylated hydroxytoluene induces neuroprotection in a streptozotocin-induced rat Alzheimer's disease model via inhibition of neuronal ferroptosis.口服丁羟甲苯诱导链脲佐菌素诱导的阿尔茨海默病大鼠模型中的神经保护作用，通过抑制神经元铁死亡。
Mol Med. 2024 Nov 8;30(1):204. doi: 10.1186/s10020-024-00980-y.
2
Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes.鉴定普罗布考为二甲双胍联合治疗 2 型糖尿病的候选药物。
NPJ Syst Biol Appl. 2023 May 23;9(1):18. doi: 10.1038/s41540-023-00275-8.
3
Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT.普罗布考防治动脉粥样硬化心血管事件的 2 项临床试验的综合分析：PROSPECTIVE 和 IMPACT。
J Atheroscler Thromb. 2022 Jun 1;29(6):850-865. doi: 10.5551/jat.62821. Epub 2021 Apr 18.
本文引用的文献
1
Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study.普罗布考和/或西洛他唑对冠心病患者颈动脉内膜中层厚度的影响：一项随机、多中心、多国研究。
J Atheroscler Thromb. 2021 Feb 1;28(2):124-136. doi: 10.5551/jat.55616. Epub 2020 Apr 24.
2
Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).普罗布考用于冠心病患者二级预防动脉粥样硬化事件的试验（前瞻性）。
J Atheroscler Thromb. 2021 Feb 1;28(2):103-123. doi: 10.5551/jat.55327. Epub 2020 Apr 24.
3
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.胆固醇酯转移蛋白：药理学中的未解之谜——拮抗剂和激动剂。
Atherosclerosis. 2018 Nov;278:286-298. doi: 10.1016/j.atherosclerosis.2018.09.035. Epub 2018 Oct 1.
4
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.亚洲缺血性脑卒中高危脑出血风险患者的心血管事件预防（PICASSO）：一项多中心、随机对照试验。
Lancet Neurol. 2018 Jun;17(6):509-518. doi: 10.1016/S1474-4422(18)30128-5.
5
Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.前瞻性试验的原理与设计：普罗布考对既往冠心病患者动脉粥样硬化事件二级预防的试验
J Atheroscler Thromb. 2016 Jun 1;23(6):746-56. doi: 10.5551/jat.32813. Epub 2016 Jan 22.
6
Did we abandon probucol too soon?我们过早放弃普罗布考了吗？
Curr Opin Lipidol. 2015 Aug;26(4):304-16. doi: 10.1097/MOL.0000000000000199.
7
Where are we with probucol: a new life for an old drug?我们对普罗布考的了解如何：一种老药的新用途？
Atherosclerosis. 2009 Nov;207(1):16-23. doi: 10.1016/j.atherosclerosis.2009.04.002. Epub 2009 Apr 11.
8
Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.长期普罗布考治疗可预防继发性心血管事件：日本杂合子家族性高胆固醇血症患者的队列研究。
J Atheroscler Thromb. 2008 Dec;15(6):292-303. doi: 10.5551/jat.e610. Epub 2008 Dec 6.
9
Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.普罗布考可能通过一种物种特异性机制增强人肝脏I型B类清道夫受体的表达。
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2422-7. doi: 10.1161/01.ATV.0000185834.98941.3d. Epub 2005 Sep 8.
10
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).普罗布考对股动脉粥样硬化的影响：普罗布考定量回归瑞典试验（PQRST）。
Am J Cardiol. 1994 Nov 1;74(9):875-83. doi: 10.1016/0002-9149(94)90579-7.
Zotero 插件